Ricardo Rojo

TL;DR: Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis and the proportion of patients who had achieved an Investigator Global Assessment response was significantly higher in the abrocITinib 100 mg group than in the placebo group.

TL;DR: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD) and laboratory values indicating thrombocytopenia.

TL;DR: In this article, the oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleucin-13 signaling, was investigated for the treatment of atopic dermatitis.

TL;DR: Reduced incidences of symptomatic malaria infection and peripheral parasitemia in the AZCQ group relative to IPTp-SP suggest thatAZCQ warrants further investigation as an alternative treatment of uncomplicated malaria.

TL;DR: In this paper, the authors investigated the efficacy and safety of oral abrocitinib plus topical therapy in adolescents with moderate-to-severe atopic dermatitis (AD) in a phase 3, randomized, double-blind, placebo-controlled study.